Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk

<p>Several new therapeutic drug classes are now available to manage lipid levels. John Wilkins, MD, MS, and Donald Lloyd-Jones, MD, ScM, of the Department of Preventive Medicine and Division of Cardiology at Northwestern University Feinberg School of Medicine, discuss the use of ezetimibe, PCSK-9 inhibitors, bempedoic acid, and icosapent ethyl to manage lipid levels in patients taking statins who require additional LDL lowering.</p> <p>Related Content:</p> <ul> <li><a href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.2244?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links"> Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk</a></li> <li><a href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2020.5685?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links"> Lipids and Lipoproteins in 2020</a></li> </ul>